BPC-157/TB-500 (Wolverine) Research Overview (also known as Tissue Repair & Recovery Protocol)
The Wolverine Stack combines BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4 fragment) for enhanced tissue repair and recovery. Named after the Marvel character known for regenerative abilities, this combination targets complementary healing pathways: BPC-157 increases actin production and promotes angiogenesis via nitric oxide modulation, while TB-500 binds actin to facilitate cell migration and reduce scarring. A 2021 clinical study showed 87.5% of patients experienced knee
What Is Wolverine Stack?
The Wolverine Stack combines BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4 fragment) for enhanced tissue repair and recovery. Named after the Marvel character known for regenerative abilities, this combination targets complementary healing pathways: BPC-157 increases actin production and promotes angiogenesis via nitric oxide modulation, while TB-500 binds actin to facilitate cell migration and reduce scarring. A 2021 clinical study showed 87.5% of patients experienced knee pain relief using BPC-157 alone or in combination with TB-4.
Mechanism of Action
BPC-157 increases actin production at gene level and modulates nitric oxide for vascular effects. TB-500 is an actin-binding protein that sequesters actin for cell migration. Together they enhance fibroblast and immune cell movement to injury sites through synergistic actin regulation.
Key Benefits
Combines complementary healing mechanisms: BPC-157 promotes angiogenesis and reduces inflammation while TB-500 enhances cell migration and reduces scarring. Clinical study showed 87.5% improvement in knee pain patients.
Quick Reference
| Literature-Reported Dose Range | 250-500 mcg BPC-157 + 250-500 mcg TB-500 |
| Literature-Reported Frequency | Once daily |
| Literature-Reported Cycle Length | 4-8 weeks |
| Literature-Reported Washout | 4 weeks between cycles |
| Storage | Lyophilized vial at room temperature before reconstitution. After reconstitution, refrigerate at 2-8°C and use within 30 days. |
| Sites Reported in Studies | Subcutaneous. Abdomen is most common. Near the affected area is an option for localized recovery. |
| Timing | Consistent daily time preferred. Morning is most common in community practice. No fasting required. |
Research Indications
Tissue Repair
Tendon & Ligament Healing
Both peptides show evidence for accelerated tendon and ligament repair. BPC-157 improved Achilles tendon healing in animal models; combination may enhance effects.
Muscle Injury Recovery
BPC-157 demonstrated enhanced muscle regeneration. TB-500 promotes cell migration essential for muscle repair. Commonly combined for athletic recovery.
Joint Pain & Cartilage
Lee & Padgett study showed 87.5% of knee pain patients improved with BPC-157/TB4. May support cartilage repair through enhanced chondrocyte activity.
Wound Healing
Accelerated Wound Closure
TB-500 Phase 2 trials showed ~1 month faster healing in ulcer patients. BPC-157 promotes angiogenesis critical for wound healing.
Reduced Scarring
Thymosin β4 decreases myofibroblasts, reducing scar formation and fibrosis. Combined approach may minimize scarring.
Surgical Recovery
Theoretical application for post-surgical healing based on individual peptide wound healing data. No direct surgical studies on combination.
Anti-Inflammatory
Inflammatory Cytokine Reduction
BPC-157 systematic review showed reduced inflammatory markers. TB-500 inhibits inflammation at injury sites.
GI Protection
BPC-157 derived from gastric protective protein. May protect against NSAID-induced GI damage while TB-500 addresses systemic inflammation.
Chronic Inflammation
Both peptides modulate inflammatory pathways through different mechanisms, potentially offering comprehensive anti-inflammatory effects.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Conservative start | 250 mcg BPC-157 + 250 mcg TB-500 | Once daily | SubQ |
| General Recovery Protocol | 500 mcg BPC-157 + 500 mcg TB-500 | Once daily | SubQ |
| General Recovery Protocol (separate vials) | BPC-157 250-500 mcg + TB-500 2 mg | BPC-157 once daily, TB-500 twice weekly | SubQ |
| Intensive Injury Recovery (separate vials) | BPC-157 500 mcg + TB-500 2.5 mg | BPC-157 1-2x daily, TB-500 twice weekly | SubQ near injury site |
Timing
Consistent daily time preferred. Morning is most common in community practice. No fasting required. Typical onset: initial effects reported at 1-2 weeks. Significant injury improvement typically reported at 4-6 weeks. Full cycle for structural repair is 4-8 weeks.
Peptide Interactions
BPC-157 upregulates GH receptors, potentially enhancing tissue repair effects. Combined use may accelerate recovery.
GH secretagogues complement the Wolverine Stack by increasing endogenous growth hormone, which supports tissue repair processes.
MGF activates satellite cells while BPC-157/TB-500 promote tissue repair through different pathways. May enhance muscle recovery.
Copper peptide promotes collagen synthesis and wound healing through different mechanisms. No negative interactions expected.
BPC-157 has shown protective effects against NSAID-induced GI damage in studies, but long-term combination effects unknown.
Steroids may counteract some healing effects. BPC-157 has shown ability to reverse some corticosteroid-induced damage in animal models.
Both peptides promote angiogenesis. Monitor for any bleeding issues when combined with blood thinners.
Angiogenesis promotion could theoretically support tumor growth. Not Recommended with any cancer history or treatment.
Reported Research Timeline
01Week 1–2 (reported in cited studies): possible reduction in acute inflammation and pain at injury sites
02Week 2–4 (reported in cited studies): noticeable improvement in recovery between workouts, reduced soreness
03Week 4–6 (reported in cited studies): significant improvement in chronic injuries, improved joint comfort
04Week 6–8 (reported in cited studies): optimal healing effects, structural improvements in damaged tissues
05Post-cycle: Benefits may persist as healed tissue maintains integrity
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Not FDA approved, research chemical only.
Not Recommended with ANY history of cancer or suspicious growths.
Both BPC-157 and TB-500 are prohibited under WADA and USADA anti-doping rules. Competitive athletes subject to drug testing should not use this stack.
Limited human safety data, most research is preclinical.
Do not combine with chemotherapy or in active malignancy.
Monitor for unusual tissue growth or changes.
Not recommended during pregnancy or breastfeeding.
Consult a healthcare provider before use, especially with existing conditions.
Seek Medical Attention If:
Any unusual lumps, growths, or rapid tissue changes
Severe injection site reactions or infections
Signs of allergic reaction (rash, swelling, difficulty breathing)
Unexpected bleeding or bruising
Persistent headaches or vision changes
Any symptoms suggesting abnormal growth
Quality Indicators
Verified Marker
White Lyophilized Powder
Both BPC-157 and TB-500 vials should contain white or off-white fluffy powder cake. Indicates proper freeze-drying.
Verified Marker
Clear After Reconstitution
When mixed with bacteriostatic water, both solutions should be crystal clear with no particles or cloudiness.
Acceptable Range
Minor Clumping Acceptable
Small clumps that dissolve completely with gentle swirling are normal. Shipping can cause minor compaction of powder.
Quality Concern
Collapsed or Discolored
If powder appears collapsed, yellowed, or stuck to vial sides, it may be degraded from heat exposure - do not use.
Quality Concern
Cloudy or Particles
Persistent cloudiness or visible particles after reconstitution indicate contamination or degradation - discard vial.
Verified Marker
Certificate of Analysis
Reputable suppliers provide HPLC purity testing (>98%) and mass spectrometry verification for both peptides.
Research Citations
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
Lee E, Padgett B, 2021, Alternative Therapies in Health and Medicine - Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
Vasireddi N, Hahamyan H, Salata MJ, et al., 2025, HSS Journal - The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients
Treadwell T, Kleinman HK, Crockford D, et al., 2012, Annals of the New York Academy of Sciences - Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications
Goldstein AL, Hannappel E, Sosne G, Kleinman HK, 2012, Expert Opinion on Biological Therapy - Prion protein mPrP[F175A](121-231): structure and stability in solution
Christen B, Hornemann S, Damberger FF, 2012, J Mol Biol
Research Focus
tissueRepair, woundHealing, antiInflammatory
Verified Vendors Carrying BPC-157/TB-500 (Wolverine)
Frequently Asked Questions
What should researchers watch for with BPC-157/TB-500 (Wolverine)?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with BPC-157/TB-500 (Wolverine)?
Week 1–2 (reported in cited studies): possible reduction in acute inflammation and pain at injury sites
How is BPC-157/TB-500 (Wolverine) typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →